Nick Mordwinkin, PharmD, PhD

Dr. Nick Mordwinkin serves as Chief Business Officer and Chief Strategy Officer at Trace Neuroscience. To this role, he brings over a decade of experience in strategy and corporate development focused in the biotechnology industry. Most recently, Nick served as Chief Business Officer and Head of Strategy at Kezar Life Sciences, where he spearheaded a strategic partnership with Everest Medicines around zetomipzomib, a first-in-class immunoproteasome inhibitor for the treatment of autoimmune diseases. Before that, he was Head of Corporate Development, Inflammation, and Fibrosis, at Gilead Sciences, where he led a variety of transactions, including partnerships and out-licensing, as well as a range of corporate development activities across the entirety of Gilead’s inflammation franchise. Prior to Gilead, Nick served as Senior Director and Head of Corporate Strategy at Ultragenyx Pharmaceutical, where he was instrumental in crafting a partnership with GeneTx Biotherapeutics in 2020 and the acquisition of Dimension Therapeutics in 2017. Nick previously co-founded and served as the President of Curium Inc., a consulting firm focused on biotech and pharmaceutical strategy. Earlier in his career, he was an Equity Research Associate at BMO Capital Markets covering SMID-cap biotechnology companies. Nick holds a B.S. in Biology and Pharm.D. from Nova Southeastern University, and a Ph.D. in Pharmaceutical Sciences from the University of Southern California. He completed his postdoctoral training at Stanford University School of Medicine.